Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 177

1.

De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial.

Clark RE, Polydoros F, Apperley JF, Milojkovic D, Rothwell K, Pocock C, Byrne J, de Lavallade H, Osborne W, Robinson L, O'Brien SG, Read L, Foroni L, Copland M.

Lancet Haematol. 2019 Jun 11. pii: S2352-3026(19)30094-8. doi: 10.1016/S2352-3026(19)30094-8. [Epub ahead of print]

PMID:
31201085
2.

Large amplicon droplet digital PCR for DNA-based monitoring of pediatric chronic myeloid leukaemia.

Krumbholz M, Goerlitz K, Albert C, Lawlor J, Suttorp M, Metzler M.

J Cell Mol Med. 2019 Jun 14. doi: 10.1111/jcmm.14321. [Epub ahead of print]

PMID:
31199062
3.

Dasatinib-induced nephrotic syndrome: a case of phenoconversion.

Mandac Rogulj I, Matišić V, Arsov B, Boban L, Juginović A, Molnar V, Primorac D.

Croat Med J. 2019 Jun 13;60(3):250-254.

4.

Conventional and molecular cytogenetic studies to characterize 32 complex variant Philadelphia translocations in patients with chronic myeloid leukemia.

Costa D, Grau J, Espinet B, Arias A, Gómez C, López-Guerra M, Nomdedeu M, Cervantes F.

Oncol Lett. 2019 Jun;17(6):5705-5710. doi: 10.3892/ol.2019.10245. Epub 2019 Apr 12.

5.

Blast crisis of chronic myeloid leukemia with plasmacytoid dendritic cell phenotype associated with a rare fusion transcript, e13a3 BCR-ABL1.

Xu D, Claudiani S, Naresh K, Mucklow S, Neelakantan P, Yebra E, Apperley JF, Khorashad J, Milojkovic D.

Leuk Lymphoma. 2019 Jun 11:1-2. doi: 10.1080/10428194.2019.1622101. [Epub ahead of print] No abstract available.

PMID:
31184233
6.

Chronic myeloid leukemia with a rare fusion transcript, b2a3 (e13a3) BCR-ABL1: A report of four cases from India.

Sazawal S, Chhikara S, Singh K, Chaubey R, Mahapatra M, Seth T, Saxena R.

South Asian J Cancer. 2019 Apr-Jun;8(2):107. doi: 10.4103/sajc.sajc_158_18. No abstract available.

7.

Low-level BCR-ABL1 transcripts in individuals without overt hematologic malignancy.

Leeman-Neill RJ, Swerdlow SH, Burnes CL, Melan MA, Nikiforova MN, Surti U, Aggarwal N.

Leuk Res. 2019 Jun;81:98-101. doi: 10.1016/j.leukres.2019.04.009. Epub 2019 Apr 22. No abstract available.

PMID:
31047698
8.

Analysis of genes encoding epigenetic regulators in myeloproliferative neoplasms: Coexistence of a novel SETBP1 mutation in a patient with a p.V617F JAK2 positive myelofibrosis.

Eder-Azanza L, Hurtado C, Navarro-Herrera D, Calavia D, Novo FJ, Vizmanos JL.

Mol Clin Oncol. 2019 Jun;10(6):639-643. doi: 10.3892/mco.2019.1840. Epub 2019 Apr 8.

9.

Efficacy and Safety of Imatinib in Paediatric CML - A Single Centre Study.

Smeding C, Szydło A, Pieluszczak K, Grzeszkiewicz K, Pawelec K.

In Vivo. 2019 May-Jun;33(3):869-875. doi: 10.21873/invivo.11552.

PMID:
31028210
10.

Results of the European survey on the assessment of deep molecular response in chronic phase CML patients during tyrosine kinase inhibitor therapy (EUREKA registry).

Möbius S, Schenk T, Himsel D, Maier J, Franke GN, Saussele S, Pott C, Andrikovics H, Meggyesi N, Machova-Polakova K, Zizkova H, Jurcek T, Mesanovic S, Zadro R, Gottardi E, Haenig J, Schuld P, Cross NCP, Hochhaus A, Ernst T.

J Cancer Res Clin Oncol. 2019 Jun;145(6):1645-1650. doi: 10.1007/s00432-019-02910-6. Epub 2019 Apr 2.

PMID:
30941573
11.

Flow cytometric predictive scoring systems for common fusions ETV6/RUNX1, BCR/ABL1, TCF3/PBX1 and rearrangements of the KMT2A gene, proposed for the initial cytogenetic approach in cases of B-acute lymphoblastic leukemia.

Tsagarakis NJ, Papadhimitriou SI, Pavlidis D, Marinakis T, Kostopoulos IV, Stiakaki E, Polychronopoulou S, Paterakis G.

Int J Lab Hematol. 2019 Jun;41(3):364-372. doi: 10.1111/ijlh.12983. Epub 2019 Feb 7.

PMID:
30730614
12.

HMGCLL1 is a predictive biomarker for deep molecular response to imatinib therapy in chronic myeloid leukemia.

Park JH, Woo YM, Youm EM, Hamad N, Won HH, Naka K, Park EJ, Park JH, Kim HJ, Kim SH, Kim HJ, Ahn JS, Sohn SK, Moon JH, Jung CW, Park S, Lipton JH, Kimura S, Kim JW, Kim DDH.

Leukemia. 2019 Jun;33(6):1439-1450. doi: 10.1038/s41375-018-0321-8. Epub 2018 Dec 16.

PMID:
30555164
13.

[MET/ERK and MET/JNK Pathway Activation Is Involved in BCR-ABL Inhibitor-resistance in Chronic Myeloid Leukemia].

Tsubaki M.

Yakugaku Zasshi. 2018;138(12):1461-1466. doi: 10.1248/yakushi.18-00142. Review. Japanese.

14.

The incidence of atypical patterns of BCR-ABL1 rearrangement and molecular-cytogenetic response to tyrosine kinase inhibitor therapy in newly diagnosed cases with chronic myeloid leukemia (CML).

Švabek ŽT, Josipović M, Horvat I, Zadro R, Davidović-Mrsić S.

Blood Res. 2018 Jun;53(2):152-159. doi: 10.5045/br.2018.53.2.152. Epub 2018 Jun 25.

15.

The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model.

Pouwer MG, Pieterman EJ, Verschuren L, Caspers MPM, Kluft C, Garcia RA, Aman J, Jukema JW, Princen HMG.

Front Cardiovasc Med. 2018 Jun 12;5:55. doi: 10.3389/fcvm.2018.00055. eCollection 2018.

16.

Early BCR-ABL1 decline in imatinib-treated patients with chronic myeloid leukemia: results from a multicenter study of the Chinese CML alliance.

Zhang J, Wang Y, Wang J, Hu J, Chen S, Jin J, Liu T, Zhou J, Hu Y, Ma D, Huang X, Ji C, Hou M.

Blood Cancer J. 2018 Jun 15;8(7):61. doi: 10.1038/s41408-018-0093-4.

17.

Chronic myelogenous leukemia on target.

Némethová V, Rázga F.

Cancer Med. 2018 Jun 14. doi: 10.1002/cam4.1604. [Epub ahead of print]

18.

Lenalidomide Induced Toxic Epidermal Necrolysis and Del (5q): Co-occurrence of Rarities.

Chaudhry QUN, Iftikhar R, Satti TM, Mahmood SK, Khan MA, Shahbaz N.

J Coll Physicians Surg Pak. 2018 Jun;28(6):S89-S90. doi: 10.29271/jcpsp.2018.06.S89.

PMID:
29866231
19.

In vivo RNAi screening identifies Pafah1b3 as a target for combination therapy with TKIs in BCR-ABL1+ BCP-ALL.

Fiedler ERC, Bhutkar A, Lawler E, Besada R, Hemann MT.

Blood Adv. 2018 Jun 12;2(11):1229-1242. doi: 10.1182/bloodadvances.2017015610.

20.

Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: the possible role of ponatinib.

Breccia M, Efficace F, Iurlo A, Luciano L, Abruzzese E, Gozzini A, Pregno P, Tiribelli M, Rosti G, Minotti G.

Expert Opin Drug Saf. 2018 Jun;17(6):623-628. doi: 10.1080/14740338.2018.1480719. Epub 2018 May 30. Review.

PMID:
29845876

Supplemental Content

Loading ...
Support Center